Breaking News

Carbogen Amcis Expands ADC Capabilities

Adds clean room clinical supply facility and upgrades sterile manufacturing

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Carbogen Amcis AG has made several investments to enhance its antibody drug conjugate (ADC) capabilities for the development of highly targeted cancer treatments. The investments include a $4 million clean room clinical supply facility at its Bubendorf, Switzerland site, and a $950,000 upgrade of its sterile manufacturing area at the facility in Riom, France.   “The new targeted cancer treatments, such as Adcetris, Kadcyla and Mylotarg, have fueled a growing demand for ADCs and we made the decis...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters